Posted by Michael Wonder on 25 Apr 2021
Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies
23 April 2021 - Application is based on Phase 2b/3 SELECTION trial data with patients with moderately to severely active ulcerative colitis.
Galapagos today report that their collaboration partner Gilead Sciences and Eisai today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis.
